Exclusive: Merck, rivals eye deal for Inhibrx experimental cancer drug tied to Keytruda, sources say

Inhibrx Biosciences has attracted interest from Merck & Co, Merck KGaA and Ono Pharmaceutical for an experimental cancer treatment that could be valued at more than $8 billion. The reported bidder interest highlights significant potential value for the asset and points to a possible major biotech transaction. The news is positive for Inhibrx, though the deal remains preliminary and valuation-driven rather than confirmed.

Analysis

Inhibrx Biosciences has attracted interest from Merck & Co, Merck KGaA and Ono Pharmaceutical for an experimental cancer treatment that could be valued at more than $8 billion. The reported bidder interest highlights significant potential value for the asset and points to a possible major biotech transaction. The news is positive for Inhibrx, though the deal remains preliminary and valuation-driven rather than confirmed.